Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium
Crossref DOI link: https://doi.org/10.1007/s00228-019-02665-6
Published Online: 2019-03-15
Published Print: 2019-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Van Wilder, Philippe http://orcid.org/0000-0001-8433-9340
Pirson, Magali
Dupont, Alain
Text and Data Mining valid from 2019-03-15
Article History
Received: 13 November 2018
Accepted: 6 March 2019
First Online: 15 March 2019